Since changes in tau PET binding are correlated with cognitive symptoms, this radiotracer provides value not only for diagnosing AD but also for tracking the spatiotemporal progression of tau pathology in longitudinal investigations (350). This evidence concerns the gene MAPT and Alzheimer disease.